Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein
P. E. Thomas, Signe Vedel‐Krogh, Pia R. Kamstrup, et al.
European Heart Journal (2023) Vol. 44, Iss. 16, pp. 1449-1460
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Marlys L. Koschinsky, Archna Bajaj, Michael B. Boffa, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 3, pp. e308-e319
Closed Access | Times Cited: 82
Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations
Aeron Small, Ashley Pournamdari, Giorgio Melloni, et al.
JAMA Cardiology (2024) Vol. 9, Iss. 4, pp. 385-385
Closed Access | Times Cited: 32
Lipoprotein(a) and cardiovascular disease
Børge G. Nordestgaard, Anne Langsted
The Lancet (2024)
Closed Access | Times Cited: 27
C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project
Natalie Arnold, Christopher Blaum, Alina Goßling, et al.
European Heart Journal (2024)
Closed Access | Times Cited: 24
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Gissette Reyes‐Soffer, Calvin Yeang, Erin D. Michos, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100651-100651
Open Access | Times Cited: 17
Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events
P. E. Thomas, Signe Vedel‐Krogh, Sune F. Nielsen, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 24, pp. 2265-2276
Open Access | Times Cited: 25
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Pia R. Kamstrup, R. Dermot G. Neely, Steven E. Nissen, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 7, pp. 903-914
Open Access | Times Cited: 10
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment
Anders Berg Wulff, Børge G. Nordestgaard, Anne Langsted
Current Atherosclerosis Reports (2024) Vol. 26, Iss. 4, pp. 111-118
Closed Access | Times Cited: 10
Waist to hip ratio modifies the cardiovascular risk of lipoprotein (a): Insights from MESA
Muhammad Imtiaz Ahmad, Parag Anilkumar Chevli, Saeid Mirzai, et al.
Progress in Cardiovascular Diseases (2025)
Closed Access | Times Cited: 1
Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay
Michael J. Wilkinson, Michael D. Shapiro
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 12, pp. 2396-2406
Closed Access | Times Cited: 6
The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease Risk
Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A. Bax, et al.
European Journal of Preventive Cardiology (2024)
Closed Access | Times Cited: 6
Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
Anastasios Makris, Fotios Barkas, Petros P. Sfikakis, et al.
Atherosclerosis Plus (2023) Vol. 54, pp. 1-6
Open Access | Times Cited: 16
High-density lipoproteins, lipoprotein(a), and remnant cholesterol: new opportunities for reducing residual cardiovascular risk
Filippo Crea
European Heart Journal (2023) Vol. 44, Iss. 16, pp. 1379-1382
Open Access | Times Cited: 15
Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Marlys L. Koschinsky, Erik S.G. Stroes, Florian Kronenberg
Pharmacological Research (2023) Vol. 194, pp. 106843-106843
Open Access | Times Cited: 14
Lipoprotein(a) association with residual risk: what has inflammation got to do with it?
Zareen Farukhi, Samia Mora
European Heart Journal (2024) Vol. 45, Iss. 12, pp. 1055-1057
Open Access | Times Cited: 5
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry
Arthur Shiyovich, Adam N. Berman, Stephanie A. Besser, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 5
Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population
Arthur Shiyovich, Adam N. Berman, Stephanie A. Besser, et al.
European Heart Journal Open (2023) Vol. 3, Iss. 4
Open Access | Times Cited: 13
Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis
Arnaud Girard, Audrey Paulin, Hasanga D. Manikpurage, et al.
Journal of the American Heart Association (2025)
Open Access
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
Niekbachsh Mohammadnia, Tjerk S.J. Opstal, Saloua El Messaoudi, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 11, pp. 1055-1059
Open Access | Times Cited: 10
Lipoprotein(a) is a highly atherogenic lipoprotein: pathophysiological basis and clinical implications
Elias Björnson, Martin Adiels, Jan Borén, et al.
Current Opinion in Cardiology (2024) Vol. 39, Iss. 6, pp. 503-510
Closed Access | Times Cited: 3
Rethinking Cardiovascular Risk: The Emerging Role of Lipoprotein(a) Screening
Victoria Clair, Francis Zirille, Edward A. Gill
American Journal of Preventive Cardiology (2025) Vol. 21, pp. 100945-100945
Open Access
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
Song Liu, Xingjin Wang, Jiaqiang Hu, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Distinct lipoprotein contributions to valvular heart disease: Insights from genetic analysis
Da Luo, Elias Björnson, Xiaoying Wang, et al.
International Journal of Cardiology (2025), pp. 133218-133218
Closed Access
Lipoproteins predicting coronary lesion complexity in premature coronary artery disease: a supervised machine learning approach
Marta Marcinkowska, Agnieszka Kuchta, Petra Małgorzata Grešner, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Interleukin-6 modifies Lipoprotein(a) and Oxidized Phospholipids Associated Cardiovascular Disease Risk in a Secondary Prevention Cohort
Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A. Bax, et al.
Atherosclerosis (2025) Vol. 405, pp. 119211-119211
Closed Access
Page 1 - Next Page

Scroll to top